Purchase Order N0018319P0765
Award Date 9/4/19
Potential Completion Date 9/1/22
Potential Value $186K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which extends through September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the established relationship between the Defense Health Agency and Cerus Corporation for blood safety technologies, with no set-aside designation...
- The Defense Health Agency awarded Cerus Corporation a firm fixed-price purchase order valued at $367.1K on October 1, 2025, for Cerus Intercept Platelet Processing Sets. The contract, which has no set-aside designation, originated from a sources sought notice posted by Tripler Army Medical Center seeking specialized blood processing equipment utilizing the INTERCEPT Blood System technology. This system employs amotosalen, a photoactive compound that uses UVA illumination to inactivate...
- The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation on July 1, 2024, with a ceiling value of $106,824 for the supply of Intercept Platelet Small Volume Sets. The contract, which runs through September 1, 2027, supports the U.S. Pacific Command Armed Services Blood Bank Center at the U.S. Naval Hospital Okinawa, Japan, and was awarded on a sole-source basis under Federal Acquisition Regulation 13.106-1(b)(1)(i), reflecting Cerus Corporation's unique...
- This is a modification to a federal contract awarded by the Office of the Secretary of Defense to Cerus Corporation, a biomedical products company, for the LYOPHILIZED PATHOGEN REDUCED CRYOPRECIPITATE (LYO-CRYO) MANUFACTURING ADVANCEMENT PROJECT. The contract, which has a ceiling value of $24,967,786.00, is an Other Transaction Agreement with no set-aside designation. The contract supports continued development of the company's INTERCEPT Blood System, a technology that uses riboflavin and...
- The Department of the Navy Bureau of Medicine and Surgery awarded a firm fixed price purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the ILLUMINATOR 60 HZ. The $119,534.60 contract has an October 10, 2017 completion date and was awarded on August 12, 2017. Cerus is a for-profit organization that has received over 20 prime federal contracts since 2002 to provide goods and services related to blood safety and pathogen reduction systems for agencies such as the...
- This is a sole-source contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies. The $193,882 firm fixed-price contract is for the supply of INTERCEPT Platelet Small Volume Processing Sets, INTERCEPT Platelet Processing Sets with Dual Storage Containers, and annual maintenance for two ILLUMINATOR systems at the Naval Hospital Guam. The contract supports the Blood Bank Department at the Naval Hospital Guam and enhances...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a for-profit manufacturer of biomedical products. The $21,955.08 contract is for the maintenance and services of the Cerus INTERCEPT Blood System located at William Beaumont Army Medical Center in Fort Bliss, Texas. The contract has a base period of one year starting on May 1, 2024 and includes two one-year option periods, bringing the potential completion date to April 30, 2027. There was no...
- This is a $11,106,465.00 definitive contract awarded by the Food and Drug Administration (FDA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System. The contract supports the "Development of an Optimized Pathogen Inactivation Process for Whole Blood" and has a period of performance through September 28, 2025. The contract was awarded under the FDA's Broad Agency Announcement (BAA) for advanced research and development proposals to support regulatory science and...